About Ixaltis
Ixaltis is a Healthcare company based in Toulouse (France) founded in 2012. It operates as a therapeutics for genito-urinary diseases including stress urinary incontinence are developed. Ixaltis has raised $8.89 million across 1 funding round from investors including IXO and Sofimac Investment Managers. Its focus areas include Life Sciences, Genitourinary Disorders and Drugs. Its competitors include Lipella, TheraVida, Esprit Pharma, Regenfro Co and Kissei Pharmaceutical and 4 more; 7 of its 9 listed competitors have raised funding.
Company details
Ixaltis was founded in 2012 in Toulouse, France, within the biotechnology sector focused on genito-urinary conditions. Therapeutics targeting diseases such as stress urinary incontinence are being advanced through clinical development. The lead product, IXA-001 (Litoxetine), was licensed from Sanofi and is undergoing Phase 12 trials to evaluate efficacy and safety in affected patients. Operations center on innovative drug candidates for unmet medical needs in this field.
- Headquarters Toulouse, France
- SectorsHealthcare
- Website ixaltis.com
- Social LinkedIn
- Total Equity Funding$8.89M (USD)
in 1 rounds
- Latest Funding Round$8.89M (USD), Series A
May 2016
- InvestorsIXO
& 1 more
Funding Insights of Ixaltis
Ixaltis has successfully raised a total of $8.89M through 1 strategic funding round. The most recent funding activity was a Series A round of $8.89 million completed in May 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.89M
- Total Rounds 1
- Last Round Series A — $8.89M
- First Round $8.89M
(May 2016)
- Investors Count 2
All 1 funding rounds of Ixaltis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2016 | $8.89M | Series A | – | – |
2 investors in total: 2 institutional.
Investors in Ixaltis
Ixaltis has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include IXO and Sofimac Investment Managers.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments in France are managed by IXO. | – | ixope.fr | Toulouse, France | |
- | – | sofimac-im.com | - |
Investor details for Ixaltis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Ixaltis
2 dated milestones of Ixaltis across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Ixaltis is founded.
- Funding First funding round of $8.9M.
Competitors of Ixaltis
Ixaltis has 9 listed competitors in our database, 7 of them funded. They include Lipella, TheraVida, Esprit Pharma, Regenfro Co and Kissei Pharmaceutical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lipella.com | 2005 | Pittsburgh, United States | $3.37M | 5 | Lipid-based therapies for common bladder syndromes are developed. | |
| theravida.com | 2005 | San Mateo, United States | $12.5M | – | Clinical stage biopharma company developing drugs for urology and central nervous system disorders | |
| espritpharma.com | 2005 | East Brunswick, United States | $219.49M | – | Develop drugs for genitourinary (GU) disorders | |
| regenephro.co.jp | 2019 | Kyoto, Japan | $28.88M | – | Developer of therapeutics to treat renal diseases | |
| kissei.co.jp | 1946 | Matsumoto, Japan | – | – | Therapies for renal diseases and urology-related anemia are developed. | |
| aceruspharma.com | 2008 | Mississauga, Canada | $38.07M | – | Develops pharmaceuticals for urology, hormone replacement therapy, and female sexual dysfunction treatments. | |
| urovant.com | 2017 | Irvine, United States | – | – | Therapies for urological disorders such as overactive bladder are developed. | |
| ixchelsis.com | 2011 | Sandwich, United Kingdom | $26M | 4 | Develops oxytocin receptor antagonists for treating genitourinary disorders. | |
| urigen.com | 1997 | North Brunswick, United States | $3.02M | – | Pain relief products for urological ailments are developed and tested. |
Detailed competitors of Ixaltis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genitourinary Disorders
10 companies that operate in the same segment as Ixaltis (Genitourinary Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | – | – | |
Provider of surgical devices for vertical hernia repair and abdominal wall reconstruction | 2012 | Malvern, Pennsylvania, United States | USD 104.6 M | USD 80.28 M | 209 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Miniaturized injectable neuromodulation devices are developed for chronic diseases. | 2014 | Santa Clara, California, United States | USD 123.59 M | – | – | |
Developer of a therapeutic solution to treat prostate, kidney, and bladder cancer | 2018 | Maple Grove, Minnesota, United States | USD 157 M | – | 29 | |
A device is developed to treat urinary obstruction from BPH. | 2014 | Palo Alto, California, United States | USD 48 M | – | 25 | |
Minimally invasive devices in urology | 2004 | Mountain View, California, United States | USD 137.96 M | – | 119 | |
Diagnostic devices for lower urinary tract diseases are developed. | 2021 | Aliso Viejo, California, United States | USD 94.99 M | – | 23 | |
Medical device for benign prostatic hyperplasia treatment is developed. | 2021 | Milwaukee, Wisconsin, United States | USD 54.16 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ixaltis
Complete news archive for Ixaltis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ixaltis
Ixaltis was founded in 2012 and raised its 1st funding round 4 years after it was founded.
Ixaltis is headquartered in Toulouse, France. It is registered at Toulouse, Occitanie, France.
Ixaltis is a funded company, having raised a total of $8.89M across 1 funding round to date. The company's 1st funding round was a Series A of $8.89M, raised on May 2016.
Ixaltis was founded in 2012 in Toulouse, France, within the biotechnology sector focused on genito-urinary conditions. Therapeutics targeting diseases such as stress urinary incontinence are being advanced through clinical development. The lead product, IXA-001 (Litoxetine), was licensed from Sanofi and is undergoing Phase 12 trials to evaluate efficacy and safety in affected patients. Operations center on innovative drug candidates for unmet medical needs in this field.
Ixaltis's top competitors include Lipella, Kissei Pharmaceutical and Regenfro Co.
Ixaltis has 2 investors. Key investors include IXO, and Sofimac Investment Managers.